Drug repurposing approach against chikungunya virus: an in vitro and in silico study
Frontiers in Cellular and Infection Microbiology · 27.04.2023 · 13
DOI: 10.3389/fcimb.2023.1132538 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 27.04.2023. Verfasst von Bhagyashri Kasabe und 8 weiteren Autor:innen. Beteiligte Einrichtung: Bioinformatics Group, Indian Council of Medical Research (ICMR)-National Institute of Virology, Pune, Maharashtra, India. Hauptthemen laut MEDLINE: Chikungunya virus, Chikungunya Fever. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Indian Council of Medical Research.
Abstract (Originalsprache)
The chikungunya virus (CHIKV) is an alphavirus transmitted by Aedes mosquitoes . There are no licenced antivirals or vaccines for treatment or prevention. Drug repurposing approach has emerged as a novel concept to find alternative uses of therapeutics to battle pathogens. In the present study, anti CHIKV activity of fourteen FDA-approved drugs was investigated by in vitro and in silico approaches. Focus-forming unit assay, immunofluorescence test, and quantitative RT-PCR assay were used to assess the in vitro inhibitory effect of these drugs against CHIKV in Vero CCL-81 cells. The findings showed that nine compounds, viz., temsirolimus, 2-fluoroadenine, doxorubicin, felbinac, emetine, lomibuvir, enalaprilat, metyrapone and resveratrol exhibit anti chikungunya activity. Furthermore, in silico molecular docking studies performed by targeting CHIKV structural and non-structural proteins revealed that these drugs can bind to structural protein targets such as envelope protein, and capsid, and non-structural proteins NSP2, NSP3 and NSP4 (RdRp). Findings from in vitro and in silico studies reveal that these drugs can suppress the infection and replication of CHIKV and further in vivo studies followed by clinical trials are warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bioinformatics Group, Indian Council of Medical Research (ICMR)-National Institute of Virology, Pune, Maharashtra, India.
- Dengue & Chikungunya Group, Indian Council of Medical Research (ICMR)-National Institute of Virology, Pune, Maharashtra, India.
Förderung
- Indian Council of Medical Research
Zitieren
APA
Kasabe, B., Ahire, G., Patil, P., Punekar, M., Davuluri, K. S., Kakade, M., Alagarasu, K., Parashar, D., & Cherian, S. (2023). Drug repurposing approach against chikungunya virus: an in vitro and in silico study. Frontiers in Cellular and Infection Microbiology, 13. https://doi.org/10.3389/fcimb.2023.1132538
Vancouver
Kasabe B, Ahire G, Patil P, Punekar M, Davuluri KS, Kakade M, et al. Drug repurposing approach against chikungunya virus: an in vitro and in silico study. Frontiers in Cellular and Infection Microbiology. 2023;13. doi:10.3389/fcimb.2023.1132538
BibTeX
@article{Kasabe2023,
author = {Kasabe, Bhagyashri and Ahire, Gunwant and Patil, Poonam and Punekar, Madhura and Davuluri, Kusuma Sai and Kakade, Mahadeo and Alagarasu, Kalichamy and Parashar, Deepti and Cherian, Sarah},
title = {Drug repurposing approach against chikungunya virus: an in vitro and in silico study},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2023},
volume = {13},
doi = {10.3389/fcimb.2023.1132538}
}
EUVIMED